Strides Pharma Science Limited has entered into a partnership with Taiwan-based TLC to distribute the latter’s liposomal amphotericin B drug in India for the treatment of Black Fungus in Covid-19 patients under the AmphoTLC brand.
The agreement between the parties follows the approval of TLC’s new drug application (NDA) of Amphotericin B Liposome for Injection 50mg (known as Ampholipad in Taiwan) from the Central Drugs Standard Control Organization (CDSCO) of India for immediate importation per approved usage and indication.
Dr R Ananthanarayanan – CEO and Managing Director of Strides Pharma Science Limited said: “We are pleased to partner with TLC for the distribution of liposomal amphotericin B. This approval from CDSCO allows us to immediately import and distribute the product in India and help ease the crisis arising out of an unprecedented rise in Covid‐19 related mucormycosis cases.
“We have expanded our Covid‐19 portfolio further with the TLC partnership and reinforced our effort and commitment to fight against this global pandemic.”
Stelis Biopharma Private Limited, the biotech division of Strides group, will import AmphoTLC from Taiwan, and will immediately distribute it in India.
Yung Shin Pharmaceutical Industrial as the contract manufacturer for AmphoTLC will manufacture the Black Fungus drug in Taiwan.
Dr. Keelung Hong – Founder, Chairman, and CEO of TLC said: “TLC appreciates the support of Indian authorities who thoroughly and expeditiously approved AmphoTLC.
“We are pleased to be able to address the current emergency in India by fulfilling an unmet need for one of the safest and most effective drugs to treat COVID‐19 patients afflicted with this debilitating infection, and we will start delivering shipments of AmphoTLC to India immediately.”
Earlier this week, Cadila Healthcare (also known as Zydus Cadila) also signed a license supply and commercialization agreement with TLC to bring the AmphoTLC Black Fungus drug to India.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
